NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Generation Bio Co. (GBIO) Stock Analysis

Generation Bio Co. (GBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GBIO

$5.34

$0.00 (0.00%)

Last trade February 10, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GBIO with… →

GBIO Key Statistics

As of Feb 10, 2026
Trading
Open
$5.34
Previous Close
$5.34
52-Week Range
3.00–7.60
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.01
Valuation
Market Cap
$35.98M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.36
EPS (ttm)Profit attributable to each share over the last twelve months.
−9.37
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−23.71%
Dividend and dates
Avg Volume
85.09K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GBIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−5.99%
2025−38.66%

As of February 10, 2026.

GBIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricGBIOBiotechnology medianvs median
P/S ratio2.3615.260.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Generation Bio Co. (GBIO) carries a market capitalisation of $35.98M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 115 employees.

Over the past 52 weeks the price has ranged from $3.00 to $7.60. GBIO last closed at $5.34 on February 10, 2026. The close was unchanged from the previous session. The latest close sits 78% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $15.27M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −9.37.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 2.36 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −23.71%. The reported beta is 2.01. Daily returns over the trailing 1 year annualize to a volatility of 103.71%.

Growth & Income

The record shows no dividend for GBIO.

The record holds one complete calendar year, 2025, which returned −38.66%. So far in 2026 the price is −5.99%.

Peer Comparison

Generation Bio Co. (GBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Generation Bio Co. GBIO $35.98M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Generation Bio Co. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of February 10, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Generation Bio Co.

Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Visit website →